Mayo Clinic's Data Analytics Platform Launches First Project
Mon, August 15, 2022

Mayo Clinic's Data Analytics Platform Launches First Project

Google can neither see nor access any data stored on Mayo's platform / Photo Credit: James R. Martin (via Shutterstock)


Mayo Clinic said it will target drug discovery in its latest initiative to improve healthcare through data insights, reported Jessica Kim Cohen of Modern Healthcare News, a website on healthcare events and trends. The clinical data analytics platform—Mayo Clinic Platform’s first project since its launch last year—is described as a "mechanism by which the data of the past can be used to improve the care of the future," said Dr. John Halamka, president of Mayo Clinic Platform. Extracting insights from data is not new, but Mayo Clinic believed the technical architecture underpinning the project will make the processes more efficient for collaborators outside the system. Its mission is to “create consistent sets of technology tools and policies for different types of collaborations.” 

For the new platform, that will mean setting up cloud containers that have de-identified patient data. This way, providers, payers, and pharmaceutical companies outside of Mayo Clinic can connect via application programming interfaces and establish standard templates for compliance and legal agreements. Halamka said it can take health systems over a year to get a partnership up and running. Mayo Clinic is an investor in Nference, the clinic’s first partner on the clinical data analytics platform. Under the partnership, researchers from both Mayo and Nference will aim to apply the latter’s tools to de-identify data stored in the clinical data analytics platform to gain insights such as identifying biomarkers for new drugs. 

While efforts to discover new therapies are the new initial focus of the platform, Halamka recommended other uses can include, enabling providers to query the platform to gain insight into patients that have the same symptom as the patient they are currently treating. Insurers can also query the platform to understand which “patients respond best to an expensive therapy.”

Andy Danielsen, chair of Mayo Clinic Ventures, the system's commercialization arm, said any revenue generated from it would be re-invested into Mayo’s clinical practice, research, and education work. He added, “Google doesn't get to see any of our data; they don't get to access any of our data there.”